Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Cardiology

Articles with lock require a GLG News subscription
Posted June 11, 2007
Medtronic Endeavor stent - 2nd generation stents are coming online
Analysis of: Two-Year Results from the Medtronic Endeavor III Trial Confirm Stent’s Positive Clinical Profile | wwwp.medtronic.com
Author: Forrest Rubenstein, Cardiac, Thoracic and Vascular Surgeon Rubenstein Cardiovascular and Thoracic Surgery
The Medtronic Endeavor III trial has been completed and the results show similar clinical outcomes compared to the Cypher stent in a controlled trial.  While the angiographic endpoints were somewhat worse for Endeavor than Cypher, the MACE rates and revascularization rates were similar.  Endeavor...
Posted June 11, 2007
Zyrtec without the side effects
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Many feel that Zyrtec is the strongest 2nd generation antihistamine on the market.[This is arquable.] It has issues with sedation though.The new formulation will have all the positive and few if any negative effects. With the push to use generics now by both medicare and managed care,...
Posted June 11, 2007
Compare it to Coreg and Toprol XL
Analysis of: Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy | pharmalive.com
Author: GLG Member Program Contributor
Beta blockers are no longer considered first line therapy for HTN. This drug may  ressurect this class of agents, but how does it compare to Coreg and Toprol? Will it also have indications for CHF, stroke etc? It  will need more than just the ability to decrease BP in obese patients to find...
Posted June 7, 2007
Idiopathic Pulmonary Haemosiderosis
Analysis of: World First Medical Treatment Announced For "Idiopathic Pulmonary Haemosiderosis | www.medicalnewstoday.com
Author: GLG Member Program Contributor
A step forward, but not a panacea
Posted June 1, 2007
Why should I prescribe this drug?
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Xyzal, or levocetirizine is a racemic version of Zyrtec, or cetirizine, which is an effective antihistamine for the treatment of allergic rhinitis and urticaria.  The problem is that the generic form of Claritin, or loratadine, is just as effective and costs much less (without the hassle of trying...
Posted May 31, 2007
Visualization is Key to Stent Placement & Deployment
Analysis of: Scrutiny of Stent Problems Turns to Doctors | online.wsj.com
Author: GLG Member Program Contributor
Many stents fail because of improper placement & deployment.  The interventional cardiologists must first select the proper size and rely heavily on the manufacturers technician/engineer.  They must also be placed properly to prevent migration and endo leaks and this is difficult without...
Posted May 31, 2007
Stenting dilemmas: Is it the Stent or the Patient?
Analysis of: Scrutiny of Stent Problems Turns to Doctors | online.wsj.com
Author: GLG Member Program Contributor
1) The article discusses the importance of IVUS and optimal deployment. 2) A major shortcoming is the failure to mention more complex lesions are being intervened (i.e. longer stent length, bifurcation) may/probably is a key factor in complications (i.e. thrombosis).
Posted May 31, 2007
This drug has little advantage of existing drugs and will be difficult to get insurance approvals
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Yet another antihistamine in a saturated market with less expensive alternatives. Antihistamines are not the drug of choice for significant allergic rhinitis
Posted May 30, 2007
I don't think this drug will be successful
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Another "me too drug" with a much cheaper over the counter alternative.
Posted May 30, 2007
Recent Trends Give Xyzal Blockbuster Potential
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: Mark Capriani, President and Chief Executive Officer AciesHealth
FDA approval for UCB / Sanofi-Aventis new prescription drug Xyzal for treatment of seasonal and perennial comes at the perfect time for a big win for the pharmaceutical companies.  Xyzal has the potential to be the next blockbuster. The key questions:  Will physicians embrace the new med;...
Previous Page : 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Next251 to 260 of 419

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353